Weekly News Round-up – 1/4/21


In the news this week, GSK agrees to support NOVAVAX vaccine production to meet UK targets. In other news, Amgen Inc. confirms its agreement to acquire Rodeo Therapeutics, and COVID-19 vaccine production is boosted by expansions in production with BioNtech and Pfizer.
GSK SUPPORTS NOVAVAX COVID 19 VACCINE MANUFACTURING – In collaboration with NOVAVAX and the UK’s Vaccines Task Force, GSK has agreed to support the manufacturing of up to 60 million COVID-19 vaccines. The recent partnership could increase production capacity and meet the April 15 deadline to offer a first dose to all over 50’s.
AMGEN TO ACQUIRE RODEO THERAPEUTICS – Under a new agreement, Amgen Inc. will acquire Rodeo Therapeutics Corporation. The strategic move by Amgen seeks to collaborate with Rodeo’s enzyme programme (15-PGDH) to develop ‘first-in-class’ therapeutics alongside Amgen’s inflammation research. Any outstanding shares of Rodeo will be acquired by Amgen in exchange for an upfront payment of $55 million.
2021 VACCINE TARGET BOOSTED BY BIONTECH-PFIZER – With further manufacturing capacity, expansion BioNTech and Pfizer could deliver 2.5 billion COVID-19 doses by 2022. The recent addition of BioNTech’s latest facility in Marburg, Germany, has resulted in expansion of the manufacturing and supply network to accelerate commercial production.
R&D
IBM unveils next steps in AI technology with quantum computer
Clinical
First cell-based gene therapy approved for Adult Multiple Myeloma by FDA
Manufacturing
Human error costs J&J 15 million COVID-19 vaccines
That’s all for now. See you next week!
Charlotte Di Salvo, Junior Medical Writer
Proventa International

The Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies
Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...
2 years agoThe Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies
Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...
2 years ago
RNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years agoRNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years ago
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years ago